Tactical insights for first-time founders to outsmart the burn, the churn & the breakdown.

Hey Founder,

In 2026, even strong companies are struggling to raise.

You’re hitting revenue targets, customers stick around, and the charts look healthy. Yet the same pattern keeps repeating: first calls go well, second calls turn into “keep us posted,” and a few weeks later, the same funds announce someone else’s round.

At some point, it starts to feel like there’s a hidden checklist other founders understand, and you somehow missed it.

Here’s the shift many founders underestimate.

Today, strong metrics and product-market fit get you in the room, but closing a Seed or Series A increasingly requires something else: Capital Market Fit (CMF) - the alignment between your stage, sector, and narrative with how a specific fund is wired to deploy capital.

This issue breaks down how CMF actually works, what “good enough” looks like at Seed vs Series A, and three moves that make your next round far more predictable by pitching only to the right investors.

In 2021, the fundraising story was simple:
Seed → PMF → Series A.
Show traction and a believable story, and someone would take the bet.

In 2026, the path is different: fewer Seed companies graduate to Series A, and even strong businesses sometimes struggle to raise follow-on rounds.
Not because they’re weak companies, but because how capital behaves has changed.

Investors aren’t just asking, “Is this a good company?”
They’re asking: “Does this fit our fund?”
Stage. Sector. Cheque size. Ownership targets. Investment thesis.

That alignment is Capital Market Fit, when your stage, category, metrics, and ambition match how a specific fund is built to deploy capital.

Take Outset, which raised a $17M Series A led by 8VC. The company helps enterprises run AI-powered qualitative research and already had customers like Nestlé and Microsoft, but the real unlock was fit: 8VC’s thesis around “smart enterprise” and IT infrastructure made Outset a natural match.

Truemed, which raised a $34M Series A led by Andreessen Horowitz. Truemed sits at the intersection of fintech and preventive health, allowing consumers to use HSA/FSA funds for lifestyle interventions - exactly the type of vertical financial infrastructure those funds actively back.

The mandates existed before these companies did.
They simply fit them.

Modern fundraising is less about building whatever category is hot and more about looking obviously fundable inside a small set of investors’ existing theses.

Most founders act like they’re taking an exam:
“If we just score high enough on ARR and growth, someone will have to fund us.”

In 2026, there is no universal passing grade.
Every fund optimises for a different “winner pattern.”

Your job isn’t to convince the whole market you’re great.
Your job is to:

1. Optionality preservation

“Come back in six months.”
“Let’s stay in touch.”
Founders often hear rejection, but investors are frequently preserving optionality. You’re interesting enough to follow, but not yet the most obvious use of their next cheque, or the fund has already backed something adjacent and wants to track the competition.

In other words, the signal is often weak, Capital Market Fit, not a hard no.

2. Series A isn’t harder. It’s later

Seed → Series A timelines have stretched by roughly a year since 2021. Many “not yet” responses reflect investors waiting for clearer proof points: retention, efficiency, or evidence that the category is durable. If those signals are forming, the timeline may have moved, not the verdict on your company.

3. Efficiency is the new traction

Across recent winners, the pattern is consistent: smaller teams, longer runway, lower burn, and cleaner unit economics.

SVB and Carta data show the same shift: revenue expectations are rising while acceptable burn multiples are tightening.

Let’s talk real numbers now…

For investors:
• Seed is “something interesting is happening here.”
• Series-A is “we know how this turns into a scalable business.”

In 2026, 30 strong updates to the right 30 investors will outperform sending 300 generic decks every time.

SVB and Carta data both show that funded companies in 2025–26 tend to have lower burn, longer runway, and more disciplined growth than the 2021 cohort.

Today, “efficient and inevitable” beats “blitzscaling and maybe.”

Think of fundraising like an operational launch.

If you can’t get your books, model, and investor list into shape within 30 days, you’re not fundraising yet.

A founder question I couldn’t help but address:

Your job isn’t to freeze everyone at their original position. Your job is to run a pay structure that still makes sense as the company grows.

Two things should be true at the same time:

In practice, that means creating simple salary bands for each role and level, and showing early employees exactly where they sit within that range.

Then make the progression explicit: if the company reaches X–Y on revenue or margin, here’s how compensation moves toward the market range over the next 6–12 months.

Once the structure is transparent, hiring someone at a higher salary no longer feels unfair. It simply reflects the market and the role’s salary band.

Send it my way, just hit reply.

This week’s essential reads:

Before You Go…

The takeaway is simple. Markets in 2026 don’t just reward good companies; they reward capital market fit.

When PMF meets CMF, fundraising stops feeling like persuasion and starts feeling like inevitability.

And that’s the real moat.

See you next Thursday,

— Mariya

Hit reply and let me know. I read every single one (for real).

Hey, I’m Mariya, a startup CFO and founder of FounderFirst. After 10 years working alongside founders at early and growth-stage startups, I know how tough it is to make the right calls when resources are tight and the stakes are high. I started this newsletter to share the practical playbook I wish every founder had from day one, packed with lessons I’ve learned (and mistakes I’ve made) helping teams scale.

Mariya Valeva

Find me on LinkedIn